Background
==========

Pyrrolizidine alkaloids (PAs) are common constituents of thousands of plant species around the world and PA-containing plants are probably the most common poisonous plants affecting livestock, wildlife, and humans. Thus, the human health risk posed by exposure to PAs has been a concern \[[@B1],[@B2]\]. Out of more than 6000 plants, about 660 PAs and their *N*-oxide derivatives have been identified, and at least half of them are genotoxic and many are tumorigenic \[[@B1]-[@B4]\]. Riddelliine is a representative genotoxic PA, and is present in plants growing in the rangelands of the western United States \[[@B5]-[@B7]\]. These plants containing riddelliine appear to enter the human food chain since riddelliine residues have been detected in meat, milk, and honey \[[@B7]\]. Riddelliine was nominated by the U.S. Food and Drug Administration to the National Toxicology Program (NTP) for genotoxicity and carcinogenicity testing due to the potential for human exposure \[[@B5]\].

Riddelliine is a 12-membered macrocyclic diester PA with an α, β-unsaturated double bond linked to the ester group at the C-7 position of the necine base. Riddelliine is completely absorbed within 30 minutes after gavage dosing to rodents and metabolized to the major metabolites, 6,7-dihydro-1-hydroxymethyl-5*H*-pyrrolizine (DHP) and riddelliine *N*-oxide, by mammalian microsomes \[[@B8]-[@B10]\]. ^32^P-Postlabeling-HPLC analysis has identified a set of DHP-derived DNA adducts from rat and human liver microsomal metabolism of riddelliine in vitro \[[@B11]\] and in the livers of rats treated in vivo \[[@B12]\]. A linear dose-dependent formation of DHP-derived DNA adducts was observed in riddelliine-treated rats \[[@B12],[@B13]\]. Riddelliine is genotoxic both in vitro and in vivo, inducing increases in sister chromatid exchange, chromosomal aberrations, unscheduled DNA synthesis, and micronucleated erythrocyte frequencies \[[@B6]\]. In the NTP carcinogenicity studies, riddelliine was tumorigenic, causing liver tumors in male mice and both sexes of rats, mononuclear cell leukemia in rats, and lung neoplasms in female mice. Riddelliine induced a high incidence of liver hemangiosarcomas (derived from endothelial cells) and lower incidences of hepatocellular carcinoma (HCC; derived from parenchymal cells) in rat liver \[[@B5],[@B6]\].

In our previous studies, we observed that riddelliine is mutagenic in the liver of riddelliine-treated rats and that the mutant frequencies (MFs) increased in a linear dose-dependent manner. Riddelliine also produced a unique mutational spectrum in the liver *cII*gene of Big Blue rats with G:C → T:A transversions being the major type of mutation \[[@B14]\]. Moreover, we found that the *cII*MF in liver endothelial cells from riddelliine-treated rats was significantly greater than the *cII*MF in endothelial cells from control rats, suggesting that the relatively high mutagenicity of riddelliine in rat liver endothelial cells may be partially responsible for the tumorigenic specificity of this agent \[[@B15]\]. It has been reported that riddelliine-treated mice and rats have higher and more persistent DNA adduct levels in liver endothelial cells than in parenchymal cells \[[@B9]\]. The sensitivity of tissues and cell types to the mutagenicity of carcinogens may be an important factor in the tissue- and cell-specificity of tumorigenesis.

Microarray technology has a profound impact on gene expression research because of its ability to examine the expression of thousands of genes at a time. The differentially expressed genes that are identified may be used to develop potential biomarkers, elucidate molecular mechanisms, and create gene signatures that identify classes of samples \[[@B16]\]. This technology, as one of the core technologies for pharmacogenomics and toxicogenomics, provides new insights into the effects of botanical chemicals on biological systems and allow the macrodissection of molecular events in botanical carcinogenesis \[[@B17],[@B18]\]. Identification of unique gene expression patterns produced by botanical carcinogens may allow us to elucidate the mechanisms of action. In this study, we treated rats with a tumorigenic dose of riddelliine and conducted microarray analysis of gene expression in the target tissue liver. We found that the gene expression profiles were significantly altered by riddelliine treatment, and many of the differentially expressed genes were involved in metabolism, injury of liver endothelial cells, liver abnormalities, and cancer development.

Results and discussion
======================

Samples and DNA microarray data analysis
----------------------------------------

Liver samples used in this study were from a previous report \[[@B14]\] in which female Big Blue rats were treated with a carcinogenic dose (1 mg/kg, 5 days per week) of riddelliine for 12 weeks. The MF in the liver *cII*gene was about 3-fold higher than those in the untreated group and the mutation spectra in the riddelliine-treated rats was significantly different from those in the control rats. In the present study, gene expression profiles were determined for the livers of control and riddelliine-treated rats using the Applied Biosystems\' Rat Genome Survey Microarray which contains 26,857 verified rat genes. Because liver tumors had not developed at the 12 week sacrifice time, the gene expression changes reflected early events in the carcinogenesis process.

After data normalized by Quantile normalization which is recommended by the manufacturer, the intensities of the whole rat gene data were analyzed by Principal Components Analysis (PCA, Figure [1](#F1){ref-type="fig"}). A separation between control and riddelliine-treated groups was observed, indicating that there was a riddelliine-treatment effect on liver gene expression. PCA analysis also demonstrates that sample \#6 from the control group appears to be different from the rest of the five sample arrays. Figure [2](#F2){ref-type="fig"} shows the pair-wise log2 intensity Pearson\'s correlation coefficients for the 6 controls samples. The correlation coefficient numbers containing samples \#6 were lower than the others. Therefore, this array was excluded from further data analysis. Differentially expressed genes were identified based on the criteria of fold-change greater than 2 (up and down) and *P*-value less than 0.01 in comparison to the control group (Figure [3](#F3){ref-type="fig"}). A total of 919 genes satisfied the requirements, of which 429 genes were up-regulated and 490 genes were down-regulated in response to riddelliine treatment. Among the differentially expressed genes, 781 were in the Ingenuity Pathway Analysis (version 3.0) database, and 238 genes were mapped to the networks. Figure [4](#F4){ref-type="fig"} shows the top 10 networks; each network was associated with specific genes and involved in different functions. The major relevant functions altered by riddelliine treatment in rat liver are listed in Table [1](#T1){ref-type="table"}. These functions include cancer, cell death, tissue development, cell morphology, cell-to-cell signaling and interaction, and cellular development. Because riddelliine treatments induce relatively high DNA adduct formation, mutation induction, and tumor incidence in the liver endothelial cells \[[@B6],[@B9],[@B14],[@B15]\], we focused our analysis on genes involved in carcinogenesis, mainly metabolism, injury of endothelial cells, liver abnormalities, and cancer development using Ingenuity Pathway Analysis.

![**Principal component analysis of gene expression profiles from livers of control and riddelliine-treated rats**. No specific cut off was applied and the intensity of whole rat genome data was used. The blue and red dots indicate control and riddelliine-treated samples, respectively.](1471-2105-8-S7-S4-1){#F1}

![**The pair-wise log2 intensity correlations within six samples of control group**. No specific cut off was applied and the intensity of whole rat genome data was used. \"L_CTR\" means liver control, and R values are shown.](1471-2105-8-S7-S4-2){#F2}

![**Volcano plots (log2 fold change vs. -log2 *P*-value)**. A gene was identified as significantly changed if the fold change was greater than 2 (up or down) and the *P*-value was less than 0.01 in comparison to the control group (red symbols). Each group consisted of 5 or 6 replicates.](1471-2105-8-S7-S4-3){#F3}

![**The pathway analysis of gene expressions for the liver of rats treated with riddelliine**. The top 10 networks were selected by Ingenuity pathway analysis database.](1471-2105-8-S7-S4-4){#F4}

###### 

The major relevant functions altered by riddelliine treatment in liver

  **Function Category**                    **Significance**     **Associated Genes**
  ---------------------------------------- -------------------- ----------------------
  Tissue Development                       2.59E-5 -- 4.05E-2   64
  Cell Morphology                          3.35E-5 -- 3.99E-2   64
  Cancer                                   8.84E-5 -- 3.99E-2   70
  Cell Death                               8.84E-5 -- 3.99E-2   66
  Cell-To-Cell Signaling and Interaction   5.51E-4 -- 4.05E-2   58
  Lipid Metabolism                         7.31E-4 -- 3.99E-2   44
  Cellular Development                     2.12E-3 -- 3.56E-2   58
  Cellular Growth and Proliferation        2.12E-3 -- 3.99E-2   37
  Cell Cycle                               3.96E-3 -- 4.04E-2   31
  Cellular Movement                        4.00E-3 -- 3.89E-2   39

Alteration of metabolizing genes
--------------------------------

Since metabolic activation of riddelliine is required for liver tumor induction \[[@B12],[@B19]\], we investigated the gene expression changes of drug metabolizing genes. Table [2](#T2){ref-type="table"} shows phases I, II, and III drug metabolizing genes whose expression was significantly changed by riddelliine treatment. Four phase 1 cytochrome P450 genes (Cyp2c12, Cyp2e1, Cyp3a9, and Cyp26) were up-regulated. Phase 2 glutathione *S*-transferase (Gsta3) and phase 3 ATP-binding cassette transporters (Abcb1a and Abcc3) were also up-regulated. In addition, there were many down-regulated genes involved in these 3 subgroups (Table [2](#T2){ref-type="table"}).

###### 

Genes involved in drug metabolisms altered by riddelliine treatment in liver

  **Gene symbol**                 **Gene description**                           **Locus link ID**   **Fold change**   ***P*-value**
  ------------------------------- ---------------------------------------------- ------------------- ----------------- ---------------
  *[Phase I metabolism]{.ul}*                                                                                          
  CYP2C                           cytochrome P450, family 2, subfamily c         29277               0.003             0.00000
  CYP2C12                         cytochrome P450, family 2, subfamily c         25011               41.89             0.00000
  CYP2C13                         cytochrome P450, family 2, subfamily c         171521              0.002             0.00000
  CYP2C22                         cytochrome P450, family 2, subfamily c         171518              0.37              0.00000
  CYP2E1                          cytochrome P450, family 2, subfamily e         25086               2.07              0.00001
  CYP3A2                          cytochrome P450, family 3, subfamily a         266682              0.002             0.00000
  CYP3A9                          cytochrome P450, family 3, subfamily a         171352              6.38              0.00000
  CYP3A18                         cytochrome P450, family 3, subfamily a         252931              0.06              0.00000
  CYP4A12                         cytochrome P450, family 4, subfamily a         266674              0.20              0.00000
  CYP26                           cytochrome P450, family 26                     154985              11.82             0.00049
  *[Phase II metabolism]{.ul}*                                                                                         
  GSTA3                           glutathione S-transferase, alpha 3             14859               11.80             0.00001
  GSTM1                           glutathione S-transferase, mu 1                24423               0.40              0.00036
  GSTM2                           glutathione S-transferase, mu 2                24424               0.48              0.00005
  *[Phase III metabolism]{.ul}*                                                                                        
  ABCB1A                          ATP-binging cassette, subfamily b (MDR/TAP)    170913              2.65              0.00001
  ABCC3                           ATP-binging cassette, subfamily c (CFTR/MRP)   140668              10.07             0.00004
  ABCC8                           ATP-binging cassette, subfamily c (CFTR/MRP)   25559               0.38              0.00001
  ABCC9                           ATP-binging cassette, subfamily c (CFTR/MRP)   25560               0.47              0.00013

The hepatic cytochrome P450 (Cyp450) metabolizing enzymes are involved in the oxidation of the necine base of PAs with the Cyp3a\'s being the major enzymes catalyzing the metabolism of retronecine-based PAs to form the genotoxic pyrrolic ester DHP and *N*-oxide derivatives \[[@B1],[@B20]\]. In addition, Cyp3a enzyme inducers (e.g., dexamethasone) and inhibitors (e.g., troleandomycin) cause increased and decreased riddelliine-induced DHP formation, respectively \[[@B11],[@B21]\]. We observed that Cyp3a9 gene expression was increased 6-fold after riddelliine treatment which is consistent with the metabolic activation findings and suggests that Cyp3a9 is the major rat liver enzyme involved in riddelliine\'s metabolic activation. In human liver, it has been shown that Cyp3a4, which is equivalent to rat Cyp3a9, catalyzes the bioactivation of PAs \[[@B20]\]. Our finding of increase expression of Cyp2e1 is consistent with data from Gordon et al. who demonstrated that retrorsine (another of the PAs) caused increased expression of hepatic Cyp2e1 in rats \[[@B22]\]. The observation that the expression of many P450 genes were down-regulated may be related to the finding that many herbal/dietary constitutes form reactive intermediates capable of irreversibly inhibiting some Cyp450 enzymes \[[@B23]\]. The down-regulated P450 genes in this study may also contribute to decreased formation of *N*-oxide derivatives, the detoxification pathway. Thus, the biological relations of these genes related to riddelliine toxicities warrant further investigations.

The glutathione pathway plays a critical role in the detoxification of many drugs and xenobiotics. However, there is a lack of information on the types and isozymes of glutathione *S*-transferases (GST) that mediate glutathione conjugation of different PAs \[[@B1]\]. In this study, we observed that Gsta3 was increased 11-fold and Gstm1 and Gstm2 were decreased about 2-fold after riddelliine treatment (Table [2](#T2){ref-type="table"}). These results imply that these particular types of GSTs may therefore be involved in the conjugative detoxification of riddelliine electrophiles and play an essential role in the cellular oxidative defense mechanisms. In addition, there were four ATP binding cassette transporter genes altered (2 up-regulated and 2 down-regulated) (Table [2](#T2){ref-type="table"}). These phase III transporters, localized to the cell membrane, play key physiological roles in drug availability, metabolism and toxicity resulting in protection of cells and tissues against xenobiotics \[[@B24]\].

Injury of liver endothelial cells
---------------------------------

Riddelliine treatments induce relatively higher DNA adduct formation, mutation induction, and tumor incidence in the liver endothelial cell than in liver parenchymal cells \[[@B6],[@B9],[@B15]\]. In this study, the gene expression changes of a number of genes involved in the injury of liver endothelial cell were detected (Table [3](#T3){ref-type="table"}). They were mainly related to cell death (Adm, F3, Tnf, Tnfrsf6, and Tnfsf10), cell movement (Edg5, Enpp2, and Il8ra), and cell-to-cell signaling and interaction (Il11, Itga4, Itga6, Lepr, and Slc7a5). We confirmed the up-regulation (2-4-fold) of previously reported Hgf, Itga4, Tnfrsf6, and Tnfsf10 \[[@B17]\], and also identified the novel up-regulated genes of Lepr, Prkca, Slc7a5, and Src (Table [3](#T3){ref-type="table"}).

###### 

Genes involved in endothelial cells altered by riddelliine treatment in liver

  **Gene**     **Description**                                              **Locus link ID**   **Fold change**   ***P*-value**
  ------------ ------------------------------------------------------------ ------------------- ----------------- ---------------
  \* ADM       adrenomedullin                                               25026               0.11              0.0010
  EDG5         endothelial differentiation, G-protein-coupled receptor, 5   29415               0.19              0.0000
  ENPP2        ectonucleotide pyrophosphatase/phosphodiesterase 2           84050               0.25              0.0000
  F11R         F11 receptor                                                 50848               0.43              0.0000
  \* F3        coagulation factor III (thromboplastin, tissue factor)       25584               0.36              0.0040
  HGF          hepatocyte growth factor (hepapoietin A; scatter factor)     24446               2.46              0.0080
  \* IL11      interleukin 11                                               171040              2.38              0.0020
  \* IL8RA     interleukin 8 receptor, alpha                                54258               2.40              0.0020
  \* ITGA4     integrin, alpha 4                                            311144              2.11              0.0020
  \* ITGA6     integrin, alpha 6                                            114517              0.35              0.0000
  LEPR         leptin receptor gene-related protein; leptin receptor        16847               3.09              0.0032
  \* PRKCA     protein kinase C, alpha                                      24680               2.41              0.0000
  SLC7A5       solute carrier family 7 member 5                             50719               4.43              0.0040
  \* SRC       v-src sarcoma viral oncogene homolog (avian)                 83805               3.33              0.0050
  \* TNF       tumor necrosis factor (TNF superfamily, member 2)            24835               0.05              0.0000
  \* TNFRSF6   Fas (TNF receptor superfamily, member 6)                     246097              3.34              0.0010
  \* TNFSF10   tumor necrosis factor (ligand) superfamily, member 10        246775              2.40              0.0020

\* Genes also involved in cancer development.

Leptin (Lep) has been consistently associated with angiogenesis and tumor growth. Leptin exerts its physiological action through its specific receptor (Lepr). Protein kinase C alpha (Prkca) is a serine/threonine protein kinase that has been implicated in the regulation of a variety of cellular functions in response to a diverse range of stimuli, and has recently become a target for anti-cancer therapies \[[@B25]\]. It has been reported that solute carrier family 7 number 5 (Slc7a5) is translated into the heavy chain of the cell surface antigen 4F2 and L-type amino acid transporter 1 and is induced by many oxidation products \[[@B26]\]. Src encodes non-receptor tyrosine kinases that are the intermediates of information transfer, and control pathways as diverse as cell growth, migration, death, and genome maintenance \[[@B27]\]. The overexpression of these genes may be responsible to the detrimental effects of riddelliine.

Also, the decreased expression of some genes, such as Adm, Edg5, and F11r, suggests a role in riddelliine-induced toxicity. The G-protein-coupled receptors were originally termed endothelial-cell-differentiation genes (EDGs) that are upregulated during endothelial cell differentiation \[[@B28]\]. Adrenomedullin (Adm) is a vasodilator peptide having a wide range of biological actions such as reduction of oxidative stress and inhibition of endothelial cell apoptosis \[[@B29]\]. The F11 receptor (F11r) plays a critical role in the function of endothelial cells and in platelet adhesion to inflamed endothelium \[[@B30]\]. Thus, reduction in the expression of these genes may result in less protection against oxidative stress leading to injury of liver endothelial cells.

Genes involved in liver abnormalities
-------------------------------------

In our previous study, we determined MFs in the liver *cII*gene of Big Blue transgenic rats treated with 0.1 to 1 mg/kg riddelliine for 12 weeks, and observed increases of MF in a linear dose-dependent manner \[[@B14]\]. The increase in MF was consistent with dose-dependent DHP-derived DNA adduct formation \[[@B12]\]. Chronic exposure to 1 mg/kg of riddelliine resulted in the alteration of a number of genes involved in liver injury and abnormalities (Table [4](#T4){ref-type="table"}). Significantly changed genes were divided into subsets based on functionality, and categories included cell death (e.g., Ahr, Igfbp1, Il15, and Prkcz), cellular growth and proliferation (e.g., Il7, Prkca, and Tgfa), oxidative stress (Mt1a, Nqo1, and Ren), and liver morphology (Igfbp2, Mthfd2, Pparg, and Tgfa).

###### 

Genes involved in liver injury and abnormalities altered by riddelliine treatment

  **Gene**     **Description**                                              **Locus link ID**   **Fold change**   ***P*-value**
  ------------ ------------------------------------------------------------ ------------------- ----------------- ---------------
  \* AHR       aryl hydrocarbon receptor                                    25690               2.03              0.0030
  \* EDG5      endothelial differentiation, G-protein-coupled receptor, 5   29415               0.19              0.0000
  \* EGR1      early growth response 1                                      24330               2.13              0.0090
  F7           coagulation factor VII                                       260320              2.22              0.0000
  HGF          hepatocyte growth factor (hepapoietin A; scatter factor)     24446               2.46              0.0080
  \* IGFBP1    insulin-like growth factor binding protein 1                 25685               3.42              0.0020
  \* IGFBP2    insulin-like growth factor binding protein 2                 25662               15.53             0.00001
  \* IL11      interleukin 11                                               171040              2.38              0.0020
  \* IL15      interleukin 15                                               25670               2.00              0.00000
  \* IL7       interleukin 7                                                25647               0.25              0.0000
  \* MMP7      matrix metalloproteinase 7 (matrilysin, uterine)             25335               0.05              0.00006
  \* MT1A      metallothionein 1A (functional)                              24567               11.10             0.0030
  MTHFD2       methylenetetrahydrofolate dehydrogenase 2,                   17768               0.33              0.0060
  \* NQO1      NAD(P)H dehydrogenase, quinone 1                             24314               2.48              0.0030
  \* PPARG     peroxisome proliferative activated receptor, gamma           25664               0.17              0.00052
  \* PRKCA     protein kinase C, alpha                                      24680               2.41              0.0000
  \* PRKCZ     protein kinase C, zeta                                       25522               3.22              0.0020
  REN          renin                                                        24715               4.48              0.0010
  \* TGFA      transforming growth factor, alpha                            24827               0.36              0.0000
  \* TNF       tumor necrosis factor (TNF superfamily, member 2)            24835               0.05              0.0000
  \* TNFRSF6   Fas (TNF receptor superfamily, member 6)                     246097              3.34              0.0010
  \* TNFSF10   tumor necrosis factor (ligand) superfamily, member 10        246775              2.40              0.0020

\* Genes also involved in cancer development.

The decreased expressions of Mthfd2, Pparg, Tgfa, and Tnf indicated that hepatic system development and function were harmed by riddelliine exposure, whereas the elevated Ahr, Igfbp1, Il15, Prkcz, Tnfrsf6, and Tnfsf10 were responsible for the cell death. Riddelliine treatment also resulted in 2- to 11-fold up-regulation of Mt1a, Nqo1, and Ren, suggesting the induction of oxidative stress. The metallothioneins (e.g., Mt1a), a family of proteins with antioxidant activity, are upregulated in response to zinc and oxidative stress \[[@B31]\]. Nqo1 gene expression is coordinately induced with other detoxifying enzyme genes in response to xenobiotics, antioxidants, oxidants, heavy metals, and radiations \[[@B32]\]. Renin (Ren) is involved in the renin-angiotensin-aldosterone system (RAS) which plays a major role in progressive liver fibrosis, and the blockade of the RAS could be effective in preventing fibrosis progression in chronic liver diseases \[[@B33]\].

Regulation of cancer development
--------------------------------

The 2-year NTP carcinogenicity study showed that riddelliine induced liver tumors in rats and male mice, lung tumors in female mice, and leukemia in rats, and that liver tumors were the cause of death for the most of these animals \[[@B5],[@B6]\]. In the present study, pathway and function analysis indicated 70 genes involved in liver cancer development (Figure [5](#F5){ref-type="fig"}), including 17 genes coding for proteins located in nucleus, 18 genes coding for proteins in the cytoplasm, 18 genes encoding plasma membrane proteins, and 15 genes encoding proteins in the extracellular space. These significantly up- and down-regulated genes were also categorized into subgroups, including ligand-dependent nuclear receptor (Ahr, Ar, and Pparg), transcription regulator (Crem, Egr1, Egr3, Hdac11, Mllt7, and Rel), phosphatase (Cdc25b and Ppp2r1e), enzyme (Akr1c3, Fut1, Mgat5, Nqo1, St6gal1, St8sia1, Fkbp5, and Smox), kinase (Map2k6, Prkca, Prkcz, Src, Chek1, Fyn, and Ntrk1), transmembrane receptor (F3, Fas, Prlr, and Tnfrsf11a), G-protein coupled receptor (Edg5 and Il8ra), growth factor (Ecgf1, Gdf15, and Tgfa), and cytokine (Il7, Il11, Il15, Tnf, Tnfsf10, and Tnfsf13). Consequently, these genes may affect multiple cellular events that contribute to riddelliine-induced toxicological pathways.

![**The cellular compartments of liver proteins involved in cancer development encoded by genes whose expression was altered by riddelliine treatment**. The different categories of proteins are indicated by the shape of the symbols.](1471-2105-8-S7-S4-5){#F5}

The early gene expression changes in the carcinogenic process may involve different genes or groups of genes, depending on the carcinogen \[[@B34]\]. Riddelliine-induced gene expression changes appeared to involve morphology, cell death or apoptosis, growth, proliferation, and binding-related genes. Among 70 genes, 11 genes were also related to injury of liver endothelial cells (Table [3](#T3){ref-type="table"}) and 18 genes were related to liver injury and abnormalities (Table [4](#T4){ref-type="table"}). Riddelliine treatment increased the level of Prlr, Ncr1, Igfbp2, Mt1A, Mt3, Ppp2r1b, and Timp3 about 250, 56, 15, 11, 8, 5, and 2-fold, respectively. It has been reported that prolactin is involved in the pathogenesis of liver cirrhosis and an accumulation of the prolactin receptor (Prlr) is observed in hepatocytes damaged by cirrhosis and fibrosis \[[@B35]\]. The surface density of the triggering receptors (e.g., Ncr1 also called NKp46) responsible for natural killer (NK) cell-mediated cytotoxicity determines the ability of NK cells to kill susceptible target cells \[[@B36]\]. The dramatic increase in Ncr1 may, therefore, indicate an increase in cells susceptible to cell-mediated toxicity. Insulin-like growth factor-binding proteins (IGFBPs) are important modulators of IGF actions, and overexpression of Igfbp2 is observed in a variety of pathological conditions. In addition, Igfbp2 is expressed in many malignant tissues including liver, and Igfbp2 appears to be a suitable marker for the evaluation of the serological status of HCC patients \[[@B37]\]. Metallothioneins (MT) are a group of low-molecular weight and cysteine rich intracellular proteins. The expression and induction of these genes (e.g., Mt1a and Mt3) have been associated with protection against DNA damage, oxidative stress and apoptosis. A number of studies have shown an increased expression of MT in various human tumors including hepatoma \[[@B38]\]. Ppp2r1b has been implicated as a tumor suppressor gene, and somatic alterations of Ppp2r1b have been detected in several cancers. Most recently, Chou et al. reported that aberrant transcripts of Ppp2r1b might be associated with the development of HCC \[[@B39]\]. Tumor-necrosis factor (TNF) is a pleiotropic cytokine that triggers physiological and pathological responses in several organs. TIMP3 is a crucial innate negative regulator of TNF in both tissue homeostasis and tissue response to injury \[[@B40]\]. Thus, the overexpression of these genes supports a critical role of them in the toxicology of riddelliine.

Conclusion
==========

The present study represents the first comprehensive in vivo examination of the chronic transcriptional response of the liver to riddelliine exposure. The available evidence on the metabolism and target-tissue specificity for riddelliine\'s tumorigenesis suggests that active metabolites of riddelliine interact with endothelial cells in the liver, which causes cell toxicity, followed by compensatory proliferation of DNA-damaged endothelial cells, \'fixation\' of the adducts into mutations in these cells, and eventual development of hemangiosarcoma and HCC. We have identified 919 genes in the livers of riddelliine-treated rats that were differentially expressed and related to these physiological and pathological outcomes. Relating the gene expression changes to phenotypic anchors such as metabolism, injury of liver endothelial cells, liver abnormalities, and cancer development, has helped in the interpretation of these data. Although the significance of all of the hundreds of gene expression changes is not fully understood, the genome-wide global information obtained herein will contribute to an improved understanding of the molecular alterations that occur after exposure to riddelliine, and provide further insight into the mechanisms involved in toxicity and carcinogenesis.

Materials and methods
=====================

Chemical and animals
--------------------

Riddelliine (\>97% pure by reversed-phase HPLC analysis) was obtained from the NTP and dissolved in 0.9% sodium chloride. Female Big Blue Fisher 344 transgenic rats were obtained from Taconic Laboratories (Germantown, NY) through purchase from Stratagene (La Jolla, CA). All animal procedures followed the recommendations of the NCTR Institutional Animal Care and Use Committee for the handling, maintenance, treatment, and sacrifice.

Riddelliine treatment
---------------------

The treatment schedule was based on the preliminary results from the NTP two-year chronic tumorigenicity bioassay \[[@B5]\]. Six-week-old Big Blue rats were treated with riddelliine at the dose of 1 mg/kg body weight by gavage five times a week for 12 weeks. Vehicle control rats were gavaged with 0.9% sodium chloride. Six rats from treatment and control groups were sacrificed one day after the last treatment. The livers were isolated, frozen quickly in liquid nitrogen, and stored at -80°C. Tumors had not developed at the 12 week sacrifice time so that gene expression changes reflected early events in the carcinogenesis process.

RNA isolation and quality control
---------------------------------

Total RNA was isolated from liver tissues of 6 control and 6 riddelliine-treated rats using an RNeasy system (Qiagen, Chatsworth, CA). The yield of the extracted RNA was determined spectrophotometrically by measuring the optical density at 260 nm. The purity and quality of extracted RNA were evaluated using the RNA 6000 LabChip and Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). RNA samples with RNA integrity numbers (RINs) greater than 8.5 were used for microarray experiments performed using Applied Biosystems\' Rat Genome Survey Microarray platform, which is a one channel microarray with chemiluminescence detection, and contains 26,857 probes (60-mer) for the interrogation of 27,088 genes and 1592 controls that track system performance through each experiment.

Preparation of digoxigenin labeled in vitro transcribed cRNA
------------------------------------------------------------

All RNA targets were labeled using the Applied Biosystems RT-IVT Labeling Kit Version 2.0. Briefly, 1.5 μg of total RNA was reverse transcribed via 2 h incubation at 42°C with ArrayScript RT enzyme (Ambion, Austin, TX) and oligo dT-T7 primer. Double stranded cDNA was produced following 2 h incubation with *E. coli*DNA polymerase and RNase H at 16°C. Double-stranded cDNA was purified according to the RT-IVT kit protocol. In vitro transcription was performed by incubation of the cDNA product with T7 RNA polymerase, 0.75 mM Digoxigenin-11-UTP (Roche Applied Science, Indianapolis, IN) and all other NTPs for 9 h. Labeled cRNA was purified according to the RT-IVT kit protocol and analyzed for quality and quantity using standard UV spectrometry and the Bioanalyzer.

Hybridization of labeled cRNA to microarrays and microarray imaging
-------------------------------------------------------------------

Digoxigenin labeled cRNA targets were hybridized to Applied Biosystems Rat Whole Genome Survey Microarrays using the Applied Biosystems Chemiluminescent Detection Kit. Briefly, 15 μg of labeled cRNA targets were fragmented via incubation with fragmentation buffer provided in the kit for 30 min at 60°C. Fragmented targets were hybridized to microarrays during a 16 h incubation at 55°C with buffers and reagents from the Chemiluminescent Detection Kit. Post-hybridization washes and anti-Digoxigenin-Alkaline Phosphatase binding were performed according to the protocol of the kit. Chemiluminescence detection, image acquisition and analysis were performed using Applied Biosystems Chemiluminescence Detection Kit and Applied Biosystems 1700 Chemiluminescent Microarray Analyzer following the manufacturer\'s protocols. Images were auto-gridded and the chemiluminescent signals were quantified, corrected for background, and finally, spot- and spatially-normalized using the Applied Biosystems 1700 Chemiluminescent Microarray Analyzer software version 1.1.

Microarray data analysis
------------------------

Raw microarray intensity data from the Applied Biosystems\' Rat Genome Survey Microarray were normalized with Quantile normalization which is recommended by the manufacturer. The normalized data were then input to ArrayTrack, a software system developed by the FDA\'s National Center for Toxicological Research for the management, analysis, visualization and interpretation of microarray data \[[@B41]\]. Chemiluminescent signals from 1529 control probes that track system performance through each experiment were not used in normalization. The identification of differentially expressed genes based on fold-change and *t*-tests cutoffs, and Principal Component Analysis were conducted within ArrayTrack. Ingenuity Pathway Analysis (Mountain View, CA) was used for network and function analysis.
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